Additional TRAVERSE data on testosterone therapy coming soon
“Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub studies,” says A. Michael Lincoff, MD.
In this video, A. Michael Lincoff, MD, discusses additional forthcoming data related to the New England Journal of Medicine study, “Cardiovascular Safety of Testosterone-Replacement Therapy.” Lincoff is vicechairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine and an interventional cardiologist in the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic in Cleveland, Ohio.
Video Transcript:
Is there anything you would like to add?
Yes, I'd like to say, "Stay tuned." Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub studies. Those are in the process of being submitted for publication and will be coming out. I'm not going to disseminate the results ahead of time, but I will say that there's a very thoughtful paper on prostate safety as well as effects on age-related anemia, sexual function, diabetes or progression from prediabetes to diabetes, and effects on bone fractures. Some of those were reported at The Endocrine Society annual meeting, but as I said, peer-reviewed publications are underway and we hope that they'll be coming out soon.
This transcription was edited for clarity.
